HRP20130204T1 - Monoklonalna protutijela koja se vežu na hgm-csf i medicinski sastavi koji ih sadrže - Google Patents
Monoklonalna protutijela koja se vežu na hgm-csf i medicinski sastavi koji ih sadrže Download PDFInfo
- Publication number
- HRP20130204T1 HRP20130204T1 HRP20130204AT HRP20130204T HRP20130204T1 HR P20130204 T1 HRP20130204 T1 HR P20130204T1 HR P20130204A T HRP20130204A T HR P20130204AT HR P20130204 T HRP20130204 T HR P20130204T HR P20130204 T1 HRP20130204 T1 HR P20130204T1
- Authority
- HR
- Croatia
- Prior art keywords
- sequence
- antigen
- antibody
- seq
- binding fragment
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 239000000427 antigen Substances 0.000 claims 29
- 102000036639 antigens Human genes 0.000 claims 29
- 108091007433 antigens Proteins 0.000 claims 29
- 239000012634 fragment Substances 0.000 claims 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 108020004414 DNA Proteins 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000036487 Arthropathies Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- 208000012659 Joint disease Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000024716 acute asthma Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 238000001516 cell proliferation assay Methods 0.000 claims 1
- 208000029771 childhood onset asthma Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 230000014509 gene expression Effects 0.000 claims 1
- 102000046157 human CSF2 Human genes 0.000 claims 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000025113 myeloid leukemia Diseases 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (24)
1. Izolirano anti-hGM-CSF monoklonalno protutijelo ili njegov fragment koji se veže na antigen, naznačen(o) time, da spomenuto protutijelo ili njegov fragment koji se veže na antigen, obuhvaća:
(a) jaki lanac koji uključuje sekvencu koja sadrži VH-CDR1, sekvencu koja sadrži VH-CDR2 i sekvencu koja sadrži VH-CDR3, pri čemu:
(i) sekvenca koja sadrži VH-CDR1 je SYGMH (SEQ ID NO: 4),
(ii) sekvenca koja sadrži VH-CDR2 je LTYHHGNRKFYADSVRG (SEQ ID NO: 5) i
(iii) sekvenca koja sadrži VH-CDR3 je ESMGAINDN (SEQ ID NO: 6); i
(b) slabi lanac koji uključuje sekvencu koja sadrži VL-CDR1, sekvencu koja sadrži VL-CDR2 i sekvencu koja sadrži VL-CDR3, pri čemu:
(i) sekvenca koja sadrži VL-CDR1 je IGNNNNIGSHAVG (SEQ ID NO: 7),
(ii) sekvenca koja sadrži VL-CDR2 je GRSPPS (SEQ ID NO: 8) i
(iii) sekvenca koja sadrži VL-CDR3 je STWDSSLSAVV (SEQ ID NO: 9).
2. Protutijelo ili njegov fragment koji se veže na antigen prema zahtjevu 1, naznačen(o) time, da se protutijelo ili njegov fragment koji se veže na antigen, povezuje na humani GM-CSF s jednim KD manjim od 400 pM.
3. Protutijelo ili njegov fragment koji se veže na antigen prema zahtjevu 1, naznačen(o) time, da protutijelo ili njegov fragment koji se veže na antigen neutralizira djelovanje od hGM-CSF, tako da protutijelo ili njegov fragment koji veže antigen ima IC50-vrijednost manju od 100 pM, kao što je utvrđeno prema ispitivanju proliferacije TF-1 na ED80.
4. Protutijelo ili njegov fragment koji se veže na antigen prema zahtjevu 1 ili 2, naznačen(o) time, da je jaki lanac odabran iz skupine koja se sastoji od gama 1 (γ1), gama 2 (γ2), gama 3 (γ3) i gama 4 (γ4).
5. Protutijelo ili njegov fragment koji se veže na antigen prema zahtjevu 4, naznačen(o) time, da jaki lanac je gama 1 (γ1).
6. Protutijelo ili njegov fragment koji se veže na antigen prema zahtjevu 4 ili 5, naznačen(o) time, da slabi lanac je lambda slabi lanac.
7. Protutijelo ili njegov fragment koji se veže na antigen prema jednom od zahtjeva 1 do 6, naznačen(o) time, da jaki lanac ima jednu amino kiselinsku sekvencu od SEQ ID NO:46 ili od SEQ ID NO: 51.
8. Protutijelo ili njegov fragment koji se veže na antigen prema zahtjevu 7, naznačen(o) time, da jaki lanac ima jednu amino kiselinsku sekvencu od SEQ ID NO:51.
9. Protutijelo ili njegov fragment koji se veže na antigen prema jednom od zahtjeva 1 do 8, naznačen(o) time, da slabi lanac ima jednu amino kiselinsku sekvencu od SEQ ID NO: 36.
10. Protutijelo ili njegov fragment koji se veže na antigen prema jednom od zahtjeva 1 do 6, naznačen(o) time, da sekvenca od varijabilnog područja jakog lanca je SEQ ID NO: 348 ili je SEQ ID NO: 361, i pri čemu sekvenca varijabilnog područja slabog lanca je SEQ ID NO: 365.
11. Protutijelo ili njegov fragment koji se veže na antigen prema zahtjevu 10, naznačen(o) time, da sekvenca od varijabilnog područja jakog lanca je SEQ ID NO: 361.
12. Protutijelo ili njegov fragment koji se veže na antigen prema jednom od zahtjeva 1 do 6, naznačen(o) time, da sekvenca jakog lanca je SEQ ID NO: 46 ili je SEQ ID NO: 51, i pri čemu sekvenca slabog lanca je SEQ ID NO: 36.
13. Protutijelo ili njegov fragment koji se veže na antigen prema zahtjevu 12, naznačen(o) time, da sekvenca jakog lanca je SEQ ID NO: 51.
14. Farmaceutski sastav, naznačen time, da obuhvaća protutijelo ili njegov fragment koji se veže na antigen, prema bilo kojem od zahtjeva 1 do 13, i farmaceutski prihvatljiv nosač.
15. Garnitura, naznačena time, da obuhvaća:
(a) protutijelo ili njegov fragment koji se veže na antigen, prema bilo kojem od zahtjeva 1 do 13, i
(b) jedan ili više spremnika koji sadrže protutijelo ili njegov fragment koji se veže na antigen.
16. Izolirana nukleinska kiselina, naznačena time, da ona kodira za anti-hGM-CSF monoklonalno protutijelo ili njegov fragment koji se veže na antigen, prema bilo kojem od zahtjeva 1 do 13.
17. Izolirana nukleinska kiselina, naznačena time, da nukleinska kiselina je DNK.
18. Vektor, naznačen time, da on obuhvaća DNK prema zahtjevu 17.
19. Stanica domaćina, naznačena time, da uključuje vektor prema zahtjevu 18, pri čemu taj vektor je vektor ekspresije.
20. Protutijelo ili njegov fragment koji se veže na antigen prema jednom od zahtjeva 1 do 13, ili farmaceutski sastav prema zahtjevu 14, naznačen(o) time, da se upotrebljava kao lijek.
21. Protutijelo ili njegov fragment koji se veže na antigen prema jednom od zahtjeva 1 do 13, ili farmaceutski sastav prema zahtjevu 14, naznačen(o) time, da se upotrebljava za liječenje subjekta od bolesti ili poremećaja koji(a) je povezan(a) s prekomjernom ekspresijom hGM-CSF.
22. Protutijelo ili njegov fragment koji se veže na antigen prema zahtjevu 21, naznačen(o) time, da se kod subjekta primjenjuje određena doza protutijela ili njegovog fragmenta koji se veže na antigen, koja ne premašuje 500 mg.
23. Protutijelo ili njegov fragment koji se veže na antigen prema zahtjevu 21 ili 22, naznačen(o) time, da je bolest ili poremećaj odabran(a) iz skupine koju čine: kronična opstrukcijska plućna bolest (COPD), astma, bronhijalna astma, pedijatrijska astma, teška astma, akutni astmatični napadaji, cistična fibroza, intersticijalna plućna bolest, rinitis, artritis i s njime povezane artropatije, reumatoidni artritis, psorijaza, mijeloidna leukemija i multipla skleroza.
24. Postupak za proizvodnju anti-hGM-CSF monoklonalnog protutijela prema zahtjevu 1 ili njegovog fragmenta koji se veže na antigen prema zahtjevu 1, te koji se veže na hGM-CSF, gdje protutijelo ili njegov fragment koji se veže na antigen obuhvaća najmanje jednu sekvencu koja sadrži VH-CDR1, jednu sekvencu koja sadrži VH-CDR2, jednu skevencu koja sadrži VH-CDR3, jednu sekvencu koja sadrži VL-CDR1, jednu sekvencu koja sadrži VL-CDR2 i jednu sekvencu koja sadrži VL-CDR3, u stanici domaćina, naznačen time, da postupak uključuje:
(i) dobivanje stanice domaćina koja obuhvaća najmanje jednu DNK sekvencu koja kodira barem za sekvencu koja sadrži VH-CDR1, sekvencu koja sadrži VH-CDR2, sekvencu koja sadrži VH-CDR3, sekvencu koja sadrži VL-CDR1, sekvencu koja sadrži VL-CDR2 te za sekvencu koja sadrži VL-CDR3, gdje:
(a) sekvenca koja sadrži VH-CDR1 je SYGMH (SEQ ID NO: 4),
(b) sekvenca koja sadrži VH-CDR2 je LTYHHGNRKFYADSVRG (SEQ ID NO: 5),
(c) sekvenca koja sadrži VH-CDR3 je ESMGAINDN (SEQ ID NO: 6),
(d) sekvenca koja sadrži VL-CDR1 je IGNNNNIGSHAVG (SEQ ID NO: 7),
(e) sekvenca koja sadrži VL-CDR2 je GRSPPS (SEQ ID NO: 8) i
(f) sekvenca koja sadrži VL-CDR3 je STWDSSLSAVV (SEQ ID NO: 9);
te
(ii) kultiviranje stanice domaćina pod prikladnim uvjetima za ekspresiju DNK i za proizvodnju protutijela ili njegovog fragmenta koji se veže na antigen.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007294945 | 2007-11-13 | ||
| JP2008052471 | 2008-02-14 | ||
| PCT/US2008/012680 WO2009064399A1 (en) | 2007-11-13 | 2008-11-12 | Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20130204T1 true HRP20130204T1 (hr) | 2013-04-30 |
Family
ID=40329216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20130204AT HRP20130204T1 (hr) | 2007-11-13 | 2013-03-08 | Monoklonalna protutijela koja se vežu na hgm-csf i medicinski sastavi koji ih sadrže |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US8679502B2 (hr) |
| EP (3) | EP2559706A1 (hr) |
| KR (1) | KR20100102108A (hr) |
| CN (2) | CN101970489B (hr) |
| AR (1) | AR069290A1 (hr) |
| AU (1) | AU2008321429A1 (hr) |
| BR (1) | BRPI0820530A2 (hr) |
| CA (1) | CA2705539A1 (hr) |
| CL (1) | CL2008003361A1 (hr) |
| CO (1) | CO6382188A2 (hr) |
| DK (1) | DK2215119T3 (hr) |
| EC (1) | ECSP10010251A (hr) |
| ES (1) | ES2401536T3 (hr) |
| HK (1) | HK1146729A1 (hr) |
| HR (1) | HRP20130204T1 (hr) |
| IL (1) | IL205576A0 (hr) |
| MA (1) | MA31899B1 (hr) |
| ME (1) | ME01005B (hr) |
| MX (1) | MX2010005291A (hr) |
| NZ (2) | NZ586027A (hr) |
| PE (1) | PE20091420A1 (hr) |
| PL (1) | PL2215119T3 (hr) |
| PT (1) | PT2215119E (hr) |
| RS (1) | RS52713B (hr) |
| RU (2) | RU2517596C2 (hr) |
| SG (1) | SG176499A1 (hr) |
| SI (1) | SI2215119T1 (hr) |
| TN (1) | TN2010000210A1 (hr) |
| TW (2) | TW201206955A (hr) |
| UY (1) | UY31466A1 (hr) |
| WO (1) | WO2009064399A1 (hr) |
| ZA (1) | ZA201003467B (hr) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| EP2160407A4 (en) * | 2007-05-23 | 2011-07-27 | Crc For Asthma And Airways Ltd | NEUTRALIZING ANTIBODIES |
| US20100297135A1 (en) * | 2007-11-12 | 2010-11-25 | Crc For Asthma And Airways Ltd. | Epitope for neutralizing antibodies |
| ES2401536T3 (es) | 2007-11-13 | 2013-04-22 | Evec Inc. | Anticuerpos monoclonales que se unen a HGM-CSF y composiciones medicinales que los comprenden |
| AR071175A1 (es) | 2008-04-03 | 2010-06-02 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| CA2736421A1 (en) | 2008-09-10 | 2010-03-18 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
| DK2376121T4 (da) * | 2008-12-22 | 2021-08-16 | Univ Melbourne | Slidgigtbehandling |
| EP2387418B1 (en) | 2008-12-22 | 2018-06-13 | The University of Melbourne | Pain treatment |
| CN102971005A (zh) | 2010-06-24 | 2013-03-13 | 贝林格尔.英格海姆国际有限公司 | 糖尿病治疗 |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| WO2013004806A1 (en) | 2011-07-06 | 2013-01-10 | Morphosys Ag | Therapeutic combinations of anti -cd20 and anti - gm - csf antibodies and uses thereof |
| KR20230041086A (ko) | 2012-09-20 | 2023-03-23 | 모르포시스 아게 | 류마티스 관절염에 대한 치료 |
| US9833410B2 (en) | 2012-10-31 | 2017-12-05 | Takeda Gmbh | Lyophilized formulation comprising GM-CSF neutralizing compound |
| AR093297A1 (es) | 2012-10-31 | 2015-05-27 | Amgen Res (Munich) Gmbh | Formulacion liquida que comprende un compuesto neutralizante de gm-csf |
| WO2014138862A1 (en) * | 2013-03-14 | 2014-09-18 | John Schrader | Human monoclonal antibodies that neutralize bioactivity of granulocyte macrophage colony-stimulating factor and methods and uses thereof |
| ES2860480T3 (es) | 2013-08-30 | 2021-10-05 | Takeda Gmbh | Anticuerpos neutralizantes de GM-CSF para su uso en el tratamiento de la artritis reumatoide o como analgésicos |
| AR100268A1 (es) | 2014-05-07 | 2016-09-21 | Takeda Gmbh | Formulación líquida que comprende compuesto neutralizante de gm-csf |
| CA3036509C (en) | 2016-09-19 | 2022-10-25 | I-Mab | Anti-gm-csf antibodies and uses thereof |
| EP3645049A4 (en) | 2017-06-25 | 2021-06-30 | Systimmune, Inc. | MULTISPECIFIC ANTIBODIES AND ASSOCIATED PREPARATION AND USE PROCESSES |
| CN111542543B (zh) * | 2017-12-28 | 2023-12-22 | 南京传奇生物科技有限公司 | 针对pd-l1的抗体及其变体 |
| US11655293B2 (en) * | 2018-02-22 | 2023-05-23 | Universitat Zurich | Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT |
| EP3623382A1 (en) * | 2018-09-14 | 2020-03-18 | Universität Zürich | Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8624899D0 (en) * | 1986-10-17 | 1986-11-19 | Sandoz Ltd | Monoclonal antibodies |
| AU3834589A (en) * | 1988-05-31 | 1990-01-05 | Schering Biotech Corporation | Method of treating myeloid leukemias |
| EP0482086A1 (en) | 1989-07-14 | 1992-04-29 | Schering Corporation | Antagonists of gm-csf derived from the carboxyl terminus |
| GB8925590D0 (en) * | 1989-11-13 | 1990-01-04 | Central Blood Lab Authority | Monoclonal antibodies |
| US6713610B1 (en) * | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
| WO1992008474A2 (en) | 1990-11-20 | 1992-05-29 | The National Heart & Lung Institute | Treatment of lung diseases |
| CA2060741A1 (en) | 1991-02-11 | 1992-08-12 | Robert S. Greenfield | Gm-csf inhibiting oligopeptides |
| US5833987A (en) * | 1995-06-07 | 1998-11-10 | Trustees Of Dartmouth College | Treatment of T cell mediated autoimmune disorders |
| US5989830A (en) * | 1995-10-16 | 1999-11-23 | Unilever Patent Holdings Bv | Bifunctional or bivalent antibody fragment analogue |
| US5662138A (en) * | 1996-06-12 | 1997-09-02 | Wang; Wen-Hsing | Drop head structure |
| US7455836B2 (en) * | 2000-05-08 | 2008-11-25 | The University Of Melbourne | Method of treatment and agents useful for same |
| ES2609016T3 (es) * | 2000-06-16 | 2017-04-18 | Human Genome Sciences, Inc. | Anticuerpos que se unen inmunoespecíficamente a BLyS |
| WO2002024865A2 (en) * | 2000-09-19 | 2002-03-28 | Microbia, Inc. | Modulation of secondary metabolite production by zinc binuclear cluster proteins |
| PE20021080A1 (es) | 2001-04-12 | 2003-02-12 | Boehringer Ingelheim Int | Un anticuerpo especifico fapo bibh1 en el tratamiento del cancer |
| US7084257B2 (en) * | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
| WO2003040341A2 (en) * | 2001-11-07 | 2003-05-15 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Anti-hepatitis a virus antibodies |
| US7381801B2 (en) * | 2002-02-13 | 2008-06-03 | Ludwig Institute For Cancer Research | Chimerized GM-CSF antibodies |
| US7193069B2 (en) * | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
| US7361740B2 (en) * | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| AR045563A1 (es) * | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| KR101237884B1 (ko) | 2003-12-03 | 2013-02-27 | 바이오제너릭스 에이지 | 글리코 peg화 과립구 콜로니 자극인자 |
| UA89364C2 (en) | 2003-12-03 | 2010-01-25 | Биодженерикс Аг | Granulocyte colony stimulating factor peptide conjugate (g-csf) |
| DK1593690T3 (da) | 2004-05-05 | 2009-11-09 | Micromet Ag | Fremstilling af ScFv-antistoffragmenter |
| WO2006011353A1 (ja) | 2004-07-30 | 2006-02-02 | Thk Co., Ltd. | ねじ溝加工方法 |
| EP1874819B1 (en) * | 2005-04-18 | 2015-05-27 | Amgen Research (Munich) GmbH | Antibody neutralizers of human granulocyte macrophage colony stimulating factor |
| ES2918209T3 (es) * | 2005-05-18 | 2022-07-14 | Morphosys Ag | Anticuerpos anti-GM-CSF y usos a partir de los mismos |
| JP4736037B2 (ja) * | 2005-10-26 | 2011-07-27 | 株式会社イーベック | ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分 |
| US7741450B2 (en) * | 2006-02-08 | 2010-06-22 | Morphotek Inc. | Antibodies to GM-CSF |
| US8398972B2 (en) * | 2006-11-21 | 2013-03-19 | Kalobios Pharmaceuticals, Inc. | Methods of treating dementia using a GM-CSF antagonist |
| EA200900709A1 (ru) | 2006-11-21 | 2009-12-30 | Калобиос Фармасьютикалс, Инк. | Способы лечения хронических воспалительных заболеваний с использованием антагониста gm-csf |
| TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| ES2401536T3 (es) | 2007-11-13 | 2013-04-22 | Evec Inc. | Anticuerpos monoclonales que se unen a HGM-CSF y composiciones medicinales que los comprenden |
-
2008
- 2008-11-12 ES ES08848696T patent/ES2401536T3/es active Active
- 2008-11-12 DK DK08848696.4T patent/DK2215119T3/da active
- 2008-11-12 KR KR1020107012568A patent/KR20100102108A/ko not_active Application Discontinuation
- 2008-11-12 NZ NZ586027A patent/NZ586027A/en not_active IP Right Cessation
- 2008-11-12 CL CL2008003361A patent/CL2008003361A1/es unknown
- 2008-11-12 SG SG2011085453A patent/SG176499A1/en unknown
- 2008-11-12 CA CA2705539A patent/CA2705539A1/en not_active Abandoned
- 2008-11-12 EP EP12192975A patent/EP2559706A1/en not_active Withdrawn
- 2008-11-12 TW TW100141459A patent/TW201206955A/zh unknown
- 2008-11-12 CN CN200880124664.1A patent/CN101970489B/zh not_active Expired - Fee Related
- 2008-11-12 BR BRPI0820530-2A patent/BRPI0820530A2/pt not_active IP Right Cessation
- 2008-11-12 CN CN201410203384.7A patent/CN104072613A/zh active Pending
- 2008-11-12 NZ NZ597023A patent/NZ597023A/xx not_active IP Right Cessation
- 2008-11-12 MX MX2010005291A patent/MX2010005291A/es active IP Right Grant
- 2008-11-12 WO PCT/US2008/012680 patent/WO2009064399A1/en active Application Filing
- 2008-11-12 AR ARP080104932A patent/AR069290A1/es active Pending
- 2008-11-12 PT PT88486964T patent/PT2215119E/pt unknown
- 2008-11-12 PE PE2008001912A patent/PE20091420A1/es not_active Application Discontinuation
- 2008-11-12 EP EP12181684A patent/EP2535353A1/en not_active Withdrawn
- 2008-11-12 US US12/681,396 patent/US8679502B2/en active Active
- 2008-11-12 UY UY31466A patent/UY31466A1/es not_active Application Discontinuation
- 2008-11-12 ME MEP-2010-89A patent/ME01005B/me unknown
- 2008-11-12 RU RU2010123693/10A patent/RU2517596C2/ru not_active IP Right Cessation
- 2008-11-12 SI SI200830911T patent/SI2215119T1/sl unknown
- 2008-11-12 PL PL08848696T patent/PL2215119T3/pl unknown
- 2008-11-12 EP EP08848696A patent/EP2215119B1/en active Active
- 2008-11-12 TW TW097143709A patent/TWI434854B/zh not_active IP Right Cessation
- 2008-11-12 RS RS20130035A patent/RS52713B/en unknown
- 2008-11-12 AU AU2008321429A patent/AU2008321429A1/en not_active Abandoned
-
2010
- 2010-05-06 IL IL205576A patent/IL205576A0/en unknown
- 2010-05-12 TN TN2010000210A patent/TN2010000210A1/fr unknown
- 2010-05-17 ZA ZA2010/03467A patent/ZA201003467B/en unknown
- 2010-06-03 MA MA32889A patent/MA31899B1/fr unknown
- 2010-06-11 CO CO10070935A patent/CO6382188A2/es active IP Right Grant
- 2010-06-14 EC EC2010010251A patent/ECSP10010251A/es unknown
-
2011
- 2011-01-27 HK HK11100827.6A patent/HK1146729A1/xx not_active IP Right Cessation
-
2013
- 2013-03-08 HR HRP20130204AT patent/HRP20130204T1/hr unknown
- 2013-09-09 RU RU2013141223/10A patent/RU2013141223A/ru not_active Application Discontinuation
-
2014
- 2014-01-28 US US14/166,803 patent/US20140205611A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20130204T1 (hr) | Monoklonalna protutijela koja se vežu na hgm-csf i medicinski sastavi koji ih sadrže | |
| Pelaia et al. | The potential of biologics for the treatment of asthma | |
| JP2014500009A5 (hr) | ||
| HRP20192076T1 (hr) | Anti-il-17a protutijela i njihova uporaba u liječenju autoimunih i upalnih poremećaja | |
| JP2018521691A5 (hr) | ||
| HRP20210393T1 (hr) | Anti-tfr antitijela i njihova uporaba u liječenju proliferativnih i upalnih poremećaja | |
| HRP20201215T1 (hr) | Ljudska anti-il-23 antitijela, sastavi, postupci i upotrebe | |
| JP2018023398A5 (hr) | ||
| CN108409860B (zh) | 抗人白细胞介素-4受体α单克隆抗体、其制备方法和应用 | |
| HRP20231579T1 (hr) | Anti-ctla-4 antitijela i postupci njihove upotrebe | |
| HRP20181085T1 (hr) | Protutijela koja vežu il-4 i/ili il-13 i njihova uporaba | |
| JP2013539369A5 (hr) | ||
| HRP20200906T1 (hr) | Il-18 vezujuće molekule | |
| JP2016520595A5 (hr) | ||
| JP2021501744A5 (hr) | ||
| JP2016135783A5 (hr) | ||
| HRP20150773T1 (hr) | Protutijela koja neutraliziraju ljudski äśimbenik stimuliranja kolonija makrofaga | |
| JP2014508511A5 (hr) | ||
| JP2008527989A5 (hr) | ||
| JP2014111644A5 (hr) | ||
| HRP20120611T1 (hr) | Anti-il-23p19 antitijela proizvedena genetiäśkim inžinjerstvom | |
| RU2013133846A (ru) | Антитела против il-18 и их применение | |
| JP2009545325A5 (hr) | ||
| RU2013143358A (ru) | Анти-fgfr4 антитела и способы их применения | |
| JP2013520984A5 (hr) |